As a global leader in the field of medical silicone technology and innovation, DuPont (NYSE: DD) is increasing its capital and resource investment to enhance its Liveo™ branded medical silicone solutions strategic capabilities. Based on its long-term commitment to the healthcare industry and its confidence in its growth potential, DuPont's investment in this round of investment focuses on enhancing innovation and production capabilities to accelerate business growth, respond to the major challenges that global megatrends bring to the industry, and continue to improve and expand Ability to serve customers.
"We are working closely with major customers to help them establish and consolidate their leading positions in the major market segments of the medical and health field." DuPont™ Liveo™ Medical Health Global Business Director Eugenio Toccalino said, "As a biopharmaceutical process, pharmaceutical solutions And a leader in the field of medical devices, we hope to empower our customers to help them gain a competitive advantage in these market segments and achieve business growth. To the value that DuPont experts bring, and what we do to meet the needs of the medical and health industry and even patients Customers have given full affirmation and appreciation for their unremitting efforts."
In order to support customers’ business development and accelerate the launch of new products, DuPont’s investment objectives include the implementation of production improvements at the Medical and Health Industrial Materials Plant (HIMS) in Hemlok, Michigan, USA to increase supply capacity. Major upgrades include the expansion of pipe extrusion capacity, the addition of an ISO 7 clean room, and the ongoing expansion of elastomer capacity-including the addition of new liquid silicone rubber (LSR) and solid silicone rubber (HCR) mixing equipment.
These investments are very important and will support the DuPont™ Liveo™ brand in continuing to address the important challenges and opportunities in the three main market segments in the healthcare sector:
· Biopharmaceutical process-through a series of Liveo™ pharmaceutical grade silicone tubing and molded components, the safe, cost-effective production of biologics for innovative drugs and vaccines is realized.
· Drug solutions-through unique topical, transdermal drug delivery solutions and gastrointestinal active pharmaceutical ingredients (API), provide a safe and effective drug delivery route for new therapeutic drugs.
· Medical devices-through a wider range of special medical adhesives and elastomer products, to achieve safe, convenient and effective diagnosis, monitoring and treatment for timely medical care, to support the development trend of connected devices and wearable devices.
“There is no doubt that these investments focusing on the future development of the medical and health industry will help strengthen and enhance the brand value of DuPont™ Liveo™ medical silicone solutions.” Mr. Eugenio Toccalino said: “We firmly believe that DuPont’s health All links in the value chain of the healthcare industry will have a positive impact."
DuPont™ Liveo™ focuses on the medical and health field and is part of the medical and health business under DuPont T&I.